Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1468
- Registration Number
- NCT00089674
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2004-08-11
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 203
- Registration Number
- NCT00089635
Subcutaneous (SC) Darbepoetin Alfa in Subjects With Symptomatic Congestive Heart Failure (CHF) & Anemia
Phase 2
Completed
- Conditions
- Congestive Heart FailureAnemia
- First Posted Date
- 2004-06-24
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT00086086
Combination Chemotherapy in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Phase 2
- Conditions
- PainProstate Cancer
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00005960
- Locations
- 🇺🇸
New York Medical College, Valhalla, New York, United States
🇺🇸Arena Oncology Associates, Great Neck, New York, United States
🇺🇸Associates of Hematology/Oncology, Upland, Pennsylvania, United States
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy
Phase 2
Completed
- Conditions
- Colorectal CancerMetastatic Cancer
- Interventions
- Biological: Panitumumab
- First Posted Date
- 2004-05-28
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 185
- Registration Number
- NCT00083616
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
Phase 2
- Conditions
- Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
- First Posted Date
- 2004-04-20
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Amgen
- Registration Number
- NCT00005958
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Center for Hematology-Oncology, Boca Raton, Florida, United States
🇺🇸Maine Center for Cancer Medicine and Blood Disorders, Scarborough, Maine, United States
Docetaxel and Vinorelbine Plus Filgrastim in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase 2
- Conditions
- Lung Cancer
- First Posted Date
- 2004-03-17
- Last Posted Date
- 2013-12-19
- Lead Sponsor
- Amgen
- Registration Number
- NCT00006215
- Locations
- 🇺🇸
Boston Baskin Cancer Group, University Tennessee Oncology/Hematology Group, Memphis, Tennessee, United States
🇺🇸Texas Cancer Care, Fort Worth, Texas, United States
🇺🇸Gould Medical Group, Modesto, California, United States
Safety and Efficacy Study of Etanercept (Enbrel®) In Children With Systemic Onset Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2019-09-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT00078806
Registry of Etanercept (Enbrel®) In Children With Juvenile Rheumatoid Arthritis
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT00078793
Etanercept (Enbrel®) in Psoriasis - Pediatrics
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2019-07-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 211
- Registration Number
- NCT00078819
© Copyright 2025. All Rights Reserved by MedPath